RESUMO
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Due to the insidious onset, poor prognosis, and lack of specificity of HCC, most patients have reached the advanced stage at the time of diagnosis. Conventional treatment methods, such as surgical resection, liver transplantation, radiotherapy, and chemotherapy, have limited therapeutic effects and fail to bring significant benefits to patients. With the improvement of science and technology and medical level in recent years, targeted therapy drugs have gradually entered people’s vision due to the breakthroughs in the treatment of HCC and thus bring new hope to patients with advanced HCC. Targeted drugs have attracted wide attention due to good molecular selectivity, targeted killing of tumor cells, and protection of normal tissue. This article reviews the research advances in targeted therapy for HCC.
RESUMO
Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase involved in many signaling pathways associated with cell growth and proliferation, and it also regulates many cellular processes. With an in-depth exploration of PP2A in the process of cell activity, especially malignant tumors, the association between PP2A and hepatocellular carcinoma (HCC) has attracted more and more attention in recent years; however, there is still a controversy over whether PP2A can promote or inhibit HCC. This article reviews the research advances in the mechanism of action of PP2A as a tumor factor in the regulation of HCC and target therapy.